
    
      The purpose of this placebo-controlled study is to determine if Xuebijing Injection treatment
      provides significant mortality reduction improvement in patients with sepsis compared with
      placebo treatment in patients receiving the current standard of care for sepsis. This study
      will also assess the effectiveness of Xuebijing Injection in reducing 28-day mortality in
      patients with sepsis.
    
  